多发性硬化症中的单克隆抗体：作用机制。
Monoclonal antibodies in MS: mechanisms of action.
机构信息
Neuroimmunological Diseases Unit, National Institute NIH, Bethesda, MD 20892, USA.
出版信息
Neurology. 2010 Jan 5;74 Suppl 1(Suppl 1):S31-40. doi: 10.1212/WNL.0b013e3181c97ed3.
Abstract
The development of monoclonal antibodies (mAbs) presents an emerging, highly specific therapeutic strategy for the treatment of multiple sclerosis (MS). mAbs target selective molecules and have shown early promise, along with notable risks, in the treatment of MS and other immune-mediated diseases. The mechanism of action of the 4 mAbs under active investigation for MS (natalizumab, rituximab, alemtuzumab, and daclizumab) are reviewed, with a discussion of how mAb interaction with each target antigen may produce direct and indirect effects (proven and hypothesized) on immune cell activity, CNS-related inflammatory processes, and clinical outcomes.
摘要
单克隆抗体 (mAbs) 的发展为多发性硬化症 (MS) 的治疗提供了一种新兴的、高度特异的治疗策略。mAbs 靶向选择性分子，在 MS 和其他免疫介导的疾病的治疗中显示出早期的希望，同时也存在显著的风险。本文综述了正在积极研究用于 MS 的 4 种 mAb（那他珠单抗、利妥昔单抗、阿仑单抗和达利珠单抗）的作用机制，并讨论了 mAb 与每个靶抗原的相互作用如何对免疫细胞活性、CNS 相关炎症过程和临床结果产生直接和间接影响（已证实和假设）。
相似文献
1
Monoclonal antibodies in MS: mechanisms of action.
Neurology. 2010 Jan 5;74 Suppl 1(Suppl 1):S31-40. doi: 10.1212/WNL.0b013e3181c97ed3.
2
Insights for practice: where mechanism of action meets patient management.
Neurology. 2010 Jan 5;74 Suppl 1:S70-3. doi: 10.1212/WNL.0b013e3181c981c0.
3
The mechanism of action of glatiramer acetate treatment in multiple sclerosis.
Neurology. 2010 Jan 5;74 Suppl 1:S25-30. doi: 10.1212/WNL.0b013e3181c97e39.
4
Mitoxantrone and cytotoxic drugs' mechanisms of action.
Neurology. 2010 Jan 5;74 Suppl 1:S41-6. doi: 10.1212/WNL.0b013e3181c97f5a.
5
Interferon-beta mechanisms of action in multiple sclerosis.
Neurology. 2010 Jan 5;74 Suppl 1:S17-24. doi: 10.1212/WNL.0b013e3181c97d99.
6
Monoclonal antibodies in treatment of multiple sclerosis.
Clin Exp Immunol. 2014 Mar;175(3):373-84. doi: 10.1111/cei.12197.
7
Monoclonal antibody treatments for multiple sclerosis.
Curr Neurol Neurosci Rep. 2008 Sep;8(5):419-26. doi: 10.1007/s11910-008-0065-3.
8
[Alemtuzumab: a further option for treatment of multiple sclerosis].
Nervenarzt. 2012 Apr;83(4):487-501. doi: 10.1007/s00115-011-3393-5.
9
Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.
CNS Drugs. 2012 Jan 1;26(1):11-37. doi: 10.2165/11596920-000000000-00000.
10
Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis.
Curr Med Chem. 2010;17(7):640-50. doi: 10.2174/092986710790416245.
引用本文的文献
1
People with Primary Progressive Multiple Sclerosis Have a Lower Number of Central Memory T Cells and HLA-DR Tregs.
Cells. 2023 Jan 29;12(3):439. doi: 10.3390/cells12030439.
2
Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes.
Neurooncol Adv. 2021 Sep 28;3(1):vdab145. doi: 10.1093/noajnl/vdab145. eCollection 2021 Jan-Dec.
3
Decreased Neurofilament L Chain Levels in Cerebrospinal Fluid and Tolerogenic Plasmacytoid Dendritic Cells in Natalizumab-Treated Multiple Sclerosis Patients - Brief Research Report.
Front Cell Neurosci. 2021 Jul 26;15:705618. doi: 10.3389/fncel.2021.705618. eCollection 2021.
4
An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis.
Cureus. 2019 Jul 26;11(7):e5246. doi: 10.7759/cureus.5246.
5
Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects.
Front Neurol. 2018 Jul 20;9:554. doi: 10.3389/fneur.2018.00554. eCollection 2018.
6
Spotlight on daclizumab: its potential in the treatment of multiple sclerosis.
Degener Neurol Neuromuscul Dis. 2016 Nov 17;6:95-109. doi: 10.2147/DNND.S85747. eCollection 2016.
7
Daclizumab Therapy for Multiple Sclerosis.
Cold Spring Harb Perspect Med. 2019 May 1;9(5):a034470. doi: 10.1101/cshperspect.a034470.
8
Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
Cochrane Database Syst Rev. 2017 Nov 27;11(11):CD010968. doi: 10.1002/14651858.CD010968.pub2.
9
Lipopolysaccharide Binding Protein and Oxidative Stress in a Multiple Sclerosis Model.
Neurotherapeutics. 2017 Jan;14(1):199-211. doi: 10.1007/s13311-016-0480-0.
10
Update on immunopathogenesis and immunotherapy in multiple sclerosis.
Immunotargets Ther. 2013 Apr 25;2:21-30. doi: 10.2147/ITT.S31813. eCollection 2013.
本文引用的文献
1
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
J Clin Invest. 2009 Jul;119(7):2052-61. doi: 10.1172/JCI37878. Epub 2009 Jun 22.
2
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Arch Neurol. 2009 Apr;66(4):483-9. doi: 10.1001/archneurol.2009.50.
3
Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.
Arch Neurol. 2009 Apr;66(4):471-9. doi: 10.1001/archneurol.2009.16.
4
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
J Neurol. 2009 Mar;256(3):405-15. doi: 10.1007/s00415-009-0093-1. Epub 2009 Mar 18.
5
Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity.
PLoS One. 2009;4(3):e4709. doi: 10.1371/journal.pone.0004709. Epub 2009 Mar 5.
6
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
Blood. 2009 May 14;113(20):4834-40. doi: 10.1182/blood-2008-10-186999. Epub 2009 Mar 5.
7
Melanoma following treatment with alemtuzumab for multiple sclerosis.
Eur J Neurol. 2009 Apr;16(4):e70-1. doi: 10.1111/j.1468-1331.2009.02552.x.
8
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.
Neurology. 2009 Feb 3;72(5):402-9. doi: 10.1212/01.wnl.0000341766.59028.9d.
9
A review of the current use of rituximab in autoimmune diseases.
Int Immunopharmacol. 2009 Jan;9(1):10-25. doi: 10.1016/j.intimp.2008.10.004. Epub 2008 Nov 8.
10
Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion.
J Invest Dermatol. 2008 Dec;128(12):2745-7. doi: 10.1038/jid.2008.330.
Zotero 插件